These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 34424870)
1. Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival. Kurth J; Kretzschmar J; Aladwan H; Heuschkel M; Gummesson A; Bergner C; Kundt G; Hakenberg OW; Krause BJ; Schwarzenböck SM Nucl Med Commun; 2021 Nov; 42(11):1217-1226. PubMed ID: 34424870 [TBL] [Abstract][Full Text] [Related]
2. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy. Michalski K; Mix M; Meyer PT; Ruf J Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145 [TBL] [Abstract][Full Text] [Related]
3. Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET, a different perspective with quantitative parameters. Aksu A; Vural Topuz Ö; Yilmaz B; Karahan Şen NP; Acar E; Çapa Kaya G Nucl Med Commun; 2022 Apr; 43(4):468-474. PubMed ID: 35045552 [TBL] [Abstract][Full Text] [Related]
5. Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy. Santo G; Di Santo G; Zelger B; Virgolini I Nuklearmedizin; 2024 Jun; 63(3):219-220. PubMed ID: 38190993 [No Abstract] [Full Text] [Related]
6. Early molecular imaging response assessment based on determination of total viable tumor burden in [ Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725 [TBL] [Abstract][Full Text] [Related]
7. Development of a Visually Calculated SUV Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L J Nucl Med; 2024 Jun; 65(6):904-908. PubMed ID: 38637137 [No Abstract] [Full Text] [Related]
8. Response assessment using Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186 [TBL] [Abstract][Full Text] [Related]
9. Heinzel A; Boghos D; Mottaghy FM; Gaertner F; Essler M; von Mallek D; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1054-1062. PubMed ID: 30697649 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Performance of RECIP 1.0 Based on [ Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363 [TBL] [Abstract][Full Text] [Related]
11. Change in total lesion PSMA (TLP) during [ Burgard C; Hein C; Blickle A; Bartholomä M; Maus S; Petto S; Schaefer-Schuler A; Ezziddin S; Rosar F Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):885-895. PubMed ID: 37889298 [TBL] [Abstract][Full Text] [Related]
12. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [ Song H; Leonio MI; Ferri V; Duan H; Aparici CM; Davidzon G; Franc BL; Moradi F; Shah J; Bergstrom CP; Fan AC; Shah S; Khaki AR; Srinivas S; Iagaru A Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2784-2793. PubMed ID: 38635050 [TBL] [Abstract][Full Text] [Related]
13. Early biochemical and radiographic response after one cycle of [ Cytawa W; Hendel R; Tomasik B; Weinzierl FX; Bley T; Jassem J; Schirbel A; Buck AK; Bundschuh RA; Hartrampf PE; Werner RA; Lapa C Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3765-3776. PubMed ID: 37474735 [TBL] [Abstract][Full Text] [Related]
15. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. Adnan A; Basu S Nucl Med Commun; 2021 May; 42(5):566-574. PubMed ID: 33560718 [TBL] [Abstract][Full Text] [Related]
16. PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease? Küper AT; Kersting D; Telli T; Herrmann K; Rominger A; Afshar-Oromieh A; Lopes L; Karkampouna S; Shi K; Kim M; Hadaschik B; Darr C; Umutlu L; Fendler WP; Seifert R Theranostics; 2024; 14(9):3623-3633. PubMed ID: 38948055 [No Abstract] [Full Text] [Related]
17. Molecular imaging and biochemical response assessment after a single cycle of [ Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047 [No Abstract] [Full Text] [Related]